← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Providence Health & Services - Oregon
Renton, WA
$4,334,231
Total funding
9
Grants
Funding over time
peak $974.9K · FY2008–25$1M$750K$500K$250K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
DOD$2,188,928 · 3
NIH$2,050,491 · 5
AHRQ$94,812 · 1
By mechanism
—$2,188,928 · 3
R01$585,976 · 1
K22$486,000 · 1
R21$419,640 · 1
R37$388,875 · 1
R03$264,812 · 2
Investigators at Providence Health & Services - Oregon
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
PRODUCTION AND CHARACTERIZATION OF A NOVEL OX40 LIGAND FOR CLINICAL USE$959,381
· FY2008 · Department of the Army
PRODUCTION OF A NOVEL 0X40 LIGAND FOR CLINICAL USE$935,176
· FY2011 · Department of Defense
Enhancing the efficacy of radiation by spatially restricting anti-TGFb treatment to the tumor$585,976
R01 · FY2025 · CA
Targeting Rheostatic Mechanisms in Melanoma$388,875
R37 · FY2025 · CA
SYNERGY OF SOCS-1 INHIBITION AND MICROBIAL-BASED CANCER VACCINES$294,371
· FY2012 · Department of Defense
DNASE1L3 regulation of anti-tumor immune responses following radiation therapy$234,218
R21 · FY2023 · CA
DNASE1L3 regulation of anti-tumor immune responses following radiation therapy$185,422
R21 · FY2024 · CA
Develop a PET radiotracer suitable for in vivo imaging of TGFβ$170,000
R03 · FY2024 · CA
DISSECTING THE ROLES OF FAT1 AND NEAT1 IN SOFT TISSUE SARCOMA DEVELOPMENT AND METASTASIS USING NOVEL IN VIVO SARCOMA MODELS$162,000
K22 · FY2024 · CA
DISSECTING THE ROLES OF FAT1 AND NEAT1 IN SOFT TISSUE SARCOMA DEVELOPMENT AND METASTASIS USING NOVEL IN VIVO SARCOMA MODELS$162,000
K22 · FY2023 · CA
DISSECTING THE ROLES OF FAT1 AND NEAT1 IN SOFT TISSUE SARCOMA DEVELOPMENT AND METASTASIS USING NOVEL IN VIVO SARCOMA MODELS$162,000
K22 · FY2022 · CA
Assessing the impact of financial incentives on provision of interpretive services in Medicaid$94,812
R03 · FY2023 · HS